[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 1992

Disseminated Histoplasmosis in Patients Receiving Low-Dose Methotrexate Therapy for Psoriasis

Author Affiliations

From the Department of Epidemiology, Ball Memorial Hospital, Muncie, Ind (Drs Witty and Steiner); the Arnett Clinic, Lafayette, Ind (Dr Curfman); Infectious Diseases of Indianapolis (Ind) (Dr Webb); and Indiana University School of Medicine, Richard L. Roudeush Veterans Administration Hospital, and Wishard Memorial Hospital, Indianapolis, Ind (Dr Wheat).

Arch Dermatol. 1992;128(1):91-93. doi:10.1001/archderm.1992.01680110101015
Abstract

• Background.—  Low-dose methotrexate sodium therapy used for nonmalignant disease has been associated with a variety of opportunistic infections with pathogens occurring in patients with defective cellular immunity. This article describes the unusual development of disseminated histoplasmosis as a probable complication of immunosuppression resulting from use of methotrexate.

Observations.—  We report the cases of three patients in whom disseminated histoplasmosis developed while receiving low-dose methotrexate therapy for psoriasis. Disease manifestations were unusually severe in two of the three patients. All three cases were disseminated, and two cases resulted in illnesses requiring intensive medical treatment. Each patient responded appropriately to antifungal treatment, although one patient has required long-term suppressive treatment because of persistent Histoplasma antigenuria. These cases illustrate the risk for opportunistic fungal infections in patients receiving low-dose methotrexate therapy for nonmalignant diseases.

Conclusions.—  Histoplasma should be added to the list of pathogens to be suspected in patients receiving such therapy.(Arch Dermatol. 1992;128:91-93)

×